Product Reports Resources Pricing Login Book a demo

TRex Bio

Biotech & Life Sciences · South San Francisco, United States · Founded 2018

TRexBio is a biotech startup that operates in the field of immune-mediated diseases. The company's primary focus is on modifying diseases at the tissue level to restore tissue homeostasis. They achieve this by leveraging a combination of modern sequencing and computational tools, along with human assay systems, to create innovative therapeutics. TRexBio serves a market that includes patients suffering from immune-mediated diseases. The company's business model revolves around the development of tissue Treg-focused therapeutics, which are designed to treat these diseases by targeting the inflammatory process and restoring tissue balance. The company differentiates itself through its unique approach, which combines a deep understanding of human tissue biology with expertise in machine learning and high throughput "-omics". This allows TRexBio to generate a detailed picture of human tissue immunobiology and the pathways that drive disease. TRexBio also emphasizes a multidisciplinary approach, combining the latest sequencing and computational tools with translational immunology and traditional drug discovery techniques. This approach is underpinned by a diverse team that values differences in backgrounds, opinions, and experiences. The company generates revenue through the development and sale of its therapeutics. As these therapeutics are designed to treat a wide range of immune-mediated diseases, the potential market for TRexBio's products is substantial. Keywords: Biotech, Immune-mediated diseases, Tissue Treg-focused therapeutics, Sequencing tools, Computational tools, Machine learning, High throughput "-omics", Translational immunology, Drug discovery, Diverse team.

Investors

13 investors on TRex Bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 10 investors entered at this stage
SV Health Investors
Pfizer Ventures
Johnson & Johnson Innovation
Alexandria Venture Investments
Eli Lilly
Polaris Partners
Laurion Capital Management
Delos Capital
Agent Capital
Avego Bioscience Capital
Series B+ 3 investors entered at this stage
Janus Henderson Investors
Balyasny Asset Management
Affinity Asset Advisors

Global footprint

Where TRex Bio has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Talent graph

The shape of TRex Bio's talent

Dealroom maps TRex Bio's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

6 team members profilednamed & role-tagged by Dealroom
61 employeestotal headcount
3 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock TRex Bio's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about TRex Bio

An AI-synthesized read of the highest-engagement posts about TRex Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TRex Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.